What are the implications of recent US Supreme Court decisions on the patent eligibility of stem cells?
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Armstrong, L. et al. Stem Cells 30, 2–9 (2012).
Schwartz, S.D. et al. Lancet 379, 713–720 (2012).
Tachibana, M. et al. Cell 153, 1228–1238 (2013).
Burrone, E. Patents at the core: the biotech business (2006). http://www.wipo.int/sme/en/documents/patents_biotech_fulltext.html
Bergman, K. & Graff, G.D. Nat. Biotechnol. 25, 419–424 (2007).
Mayo v. Prometheus, 566 US 132 (2012).
Parker v. Flook, 437 US 584 (1978).
Hirshfeld, A.H. 2012 Interim Procedure for Subject Matter Eligibility Analysis of Process Claims Involving Laws of Nature (USPTO memorandum, 3 July 2012). http://www.uspto.gov/patents/law/exam/2012_interim_guidance.pdf
Rogers, E.J. J. Pat. Trademark Off. Soc. 19, 93 (2011).
Ass'n v. USPTO, 702 F. Supp. 2d 181 (S.D.N.Y., 2010).
Ass'n v. USPTO, 653 F. 3d 1329 (2011).
Ass'n v. USPTO, 689 F. 3d 1303 (2012).
Ass'n v. Myriad, 569 US 12–398 (2013).
Hirshfeld, A.H. Supreme Court Decision in Association for Molecular Pathology v. Myriad Genetics, Inc. (USPTO memorandum, 13 June 2013). http://www.uspto.gov/patents/law/exam/myriad_20130613.pdf
Hirshfeld, A.H. 2014 Procedure for Subject Matter Eligibility Analysis of Claims Reciting or Involving Laws of Nature/Natural Principles, Natural Phenomena, and/or Natural Products (USPTO memorandum, 4 March, 2014). http://www.uspto.gov/patents/law/exam/myriad-mayo_guidance.pdf
Zuhn, D.L. USPTO Holds Forum on Subject Matter Eligibility—Part I (Patent Docs, 12 May 2014). http://www.patentdocs.org/2014/05/uspto-holds-forum-on-subject-matter-eligibility-part-i.html
Zuhn, D.L. USPTO Holds Forum on Subject Matter Eligibility—Part III (Patent Docs, 15 May 2014). http://www.patentdocs.org/2014/05/uspto-holds-forum-on-subject-matter-eligibility-part-iii.html
Offit, K. et al. J. Clin. Oncol. 31, 2743–2748 (2013).
Rosenfeld, J.A. & Mason, C.E. Genome Med. 5, 27 (2013).
Thomson, J.A. US Patent No. 6,200,806 (2001).
Section 27 of Leahy-Smith America Invents Act. Public Law 112-29 (2011).
In re Bilski, 545 F.3d 943 (2008).
We thank N. Yi-Chen Su for insights into and comments on this article.
The authors declare competing financial interests: details are available in the online version of the paper (doi:10.1038/nbt.2945).
About this article
Cite this article
Chan, AK., Wong, AT. & Lee, HM. A patent perspective on US stem cell research. Nat Biotechnol 32, 633–637 (2014). https://doi.org/10.1038/nbt.2945
A “Ray of Hope” for European Stem Cell Patents or “Out of the Smog into the Fog”? An Analysis of Recent European Case Law and How it Compares to the US
IIC - International Review of Intellectual Property and Competition Law (2016)